Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib for the potential treatment of Fibrostenosing Crohn’s Disease.
Agomab announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib for the potential treatment of Fibrostenosing Crohn’s Disease.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.